A族β溶血性链球菌耐药  

Resistance of Group A β -hemolytic streptococcus

作　　者：梁云梅[1] 李苗[1] 呙芳[1] 张金[1] 任思其[1] 

机构地区：[1]首都医科大学附属北京世纪坛医院儿科,100038

出　　处：《中华实用儿科临床杂志》2016年第4期244-247,共4页Chinese Journal of Applied Clinical Pediatrics

摘　　要：A族β溶血性链球菌（GAS）即酿脓链球菌，是人类最重要的病原体之一，可导致皮肤、黏膜浅表感染性疾病，危及生命的侵袭性疾病，毒素介导性疾病及免疫相关性疾病。抗生素是控制GAS菌感染的有效手段，β-内酰胺类抗生素是治疗GAS感染的首选药物，大环内酯类抗生素常作为阻断GAS外毒素产物的手段或对β-内酰胺类抗生素过敏患者替代治疗药物而被推荐。但随着大环内酯类抗生素的广泛使用，大环内酯类抗生素耐药GAS在全球范围内播散，成为全球关注的问题。现将对GAS对大环内酯类抗生素耐药情况进行阐述。Group A β -hemolytic streptococcus （GAS） , namely Streptococcus pyogenes,is one of the most important human pathogen. GAS can cause skin and mucous membrane superficial infectious diseases, life - threatening invasive disease,toxin - mediated diseases and immune - related diseases. Antibiotic is an effective mean to control GAS infection. The β- lactam antibiotics remain the first - choice treatment for GAS infection and the macrolides are often recommended as a replacement therapy for β - lactam antibiotics allergic patients or a means to blocking GAS exotoxin product. But with the widespread use of macrolides autibiotics, macrolide - resistant GAS spread in the world. This paper will elaborate the situation of macrolide - resistant clones.

关 键 词：A族Β溶血性链球菌 大环内酯类抗生素 耐药 

分 类 号：R446.5[医药卫生—诊断学]